Intracerebroventricular valproate: Ph I/II ADDRESS started

Cerebral Therapeutics began the Australian Phase I/II ADDRESS trial to evaluate intracerebroventricular valproate delivered via the implantable Prometra II drug pump system in 12 patients. The double-...